DGAP-News: Aladdin Healthcare Technologies becomes a sponsor of University College London's (UCL) Industry Exchange Network (IXN) Programme

Aladdin Healthcare Technologies becomes a sponsor of University College London's (UCL) Industry Exchange Network (IXN) Programme

BERLIN/LONDON, July 28, 2020 - Aladdin Healthcare Technologies SE ("Aladdin", ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, was appointed last week as an official sponsor of the University College London's (UCL) Industry Exchange Network (IXN) programme.

This partnership enables Aladdin to work closely with the Computer Science department of UCL and to work with gifted graduate students from one of the world's leading universities. Other sponsors in the same IXN programme include global industry leaders such as DeepMind, IBM, Facebook, Amazon, JP Morgan. UCL is home to some of the most influential and creative researchers in the field of Computer Science. The Computer Science department of UCL has made a deep and lasting impact on all aspects of society, from medical image analysis to deep learning development and was ranked amongst the top 20 in the world, according to Times Higher Education (THE) in 2019.

UCL's sponsorship programme aims to build close relationships with companies that share the ambition to create and develop an innovative and diverse learning experience for the students. In addition to this UCL aims to meet the business objectives of the sponsors, providing return on investment, increased brand awareness and influence amongst the students and academics, and most importantly a positive partnership experience with the UCL Computer Science Department.

Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies SE, comments: "This summer Aladdin has taken on 4 leading master students as interns from more than 40 applicants from UCL and Imperial College London. 3 of the students have previous degrees from Oxford University and Cambridge University, another one holds a bachelor degree from the University of Edinburgh. This shows Aladdin is setting a high standard on recruiting and aiming to build the best-in-class team, which consists of both senior AI award winners and passionate juniors."
 

About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets age-related diseases including a significant focus on Alzheimer's disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose age-related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.

Website Link: www.aladdinid.com
GSIN: A12ULL
ISIN: DE000A12ULL2
TICKER SYMBOL: NMI

For further information:

Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696
Email: info@aladdinid.com

Contact Press
CROSS ALLIANCE communication GmbH
Sara Pinto
Phone +49 89 1250 90330
Email: pi@crossalliance.de
www.crossalliance.de